Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT W LEVIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1326066903
CMS profile
195766
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$84,628.49

271 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT W LEVIN

NPI 1326066903 · CMS profile ID 195766

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT W LEVIN, NPI 1326066903, CMS profile ID 195766. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBERT W LEVIN, NPI 1326066903, CMS profile ID 195766. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBERT W LEVIN, NPI 1326066903, CMS profile ID 195766, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

271 matching records · $84,628.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 271 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 271.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $10.4004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115867592 CMS
Amgen Inc. $21.2404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115867456 CMS
Janssen Biotech, Inc. $150.0004/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078406821 CMS
Novartis Pharmaceuticals Corporation $110.3604/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086963592 CMS
GENZYME CORPORATION $37.5704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139630317 CMS
ABBVIE INC. $22.8604/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104166000 CMS
Amgen Inc. $11.8104/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115867526 CMS
Fresenius Kabi USA, LLC $27.0504/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146955558 CMS
TerSera Therapeutics LLC $28.6804/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144717938 CMS
ABBVIE INC. $26.9604/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104165998 CMS
E.R. Squibb & Sons, L.L.C. $23.9004/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101671260 CMS
Mallinckrodt Hospital Products Inc. $27.9904/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145098912 CMS
GENZYME CORPORATION $37.4304/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139630323 CMS
Mallinckrodt Hospital Products Inc. $2.5704/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145098908 CMS
Novartis Pharmaceuticals Corporation $23.0503/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086963590 CMS
Lilly USA, LLC $22.8603/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135357033 CMS
Janssen Biotech, Inc. $2.5503/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078406133 CMS
Amgen Inc. $19.6103/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115867583 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.9803/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963790 CMS
Aurinia Pharma U.S., Inc. $30.6203/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150686139 CMS
UCB, Inc. $19.6603/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143096651 CMS
GlaxoSmithKline, LLC. $116.9703/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116340150 CMS
GlaxoSmithKline, LLC. $30.9903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116390856 CMS
Organon Llc $6.5003/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136261185 CMS
PFIZER INC. $18.4603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131804999 CMS
Fresenius Kabi USA, LLC $19.2603/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146955548 CMS
UCB, Inc. $16.0503/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143096649 CMS
UCB, Inc. $0.8603/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143096647 CMS
Mallinckrodt Hospital Products Inc. $28.7303/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145098900 CMS
Mallinckrodt Hospital Products Inc. $3.2203/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145098904 CMS
Janssen Biotech, Inc. $114.6703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078405833 CMS
Janssen Biotech, Inc. $137.5702/29/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176587905 CMS
ABBVIE INC. $69.5302/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104165996 CMS
Amgen Inc. $18.8002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115867448 CMS
ABBVIE INC. $19.4202/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104165994 CMS
GlaxoSmithKline, LLC. $358.8902/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116466314 CMS
Janssen Biotech, Inc. $30.5002/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078405977 CMS
GlaxoSmithKline, LLC. $29.3502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115984102 CMS
UCB, Inc. $13.0302/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143096645 CMS
PFIZER INC. $24.5002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131798516 CMS
Lilly USA, LLC $18.7602/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135337645 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.6602/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963760 CMS
Novartis Pharmaceuticals Corporation $31.2402/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086963582 CMS
UCB, Inc. $14.9002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143096643 CMS
GlaxoSmithKline, LLC. $1.4002/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116577126 CMS
GlaxoSmithKline, LLC. $650.0002/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116523754 CMS
Fresenius Kabi USA, LLC $15.0202/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146955546 CMS
GENZYME CORPORATION $111.3102/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139630311 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.2602/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963794 CMS
Amgen Inc. $20.9401/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115867438 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $53,955.87 193
PY2020 $20,069.81 123
PY2021 $21,544.55 191
PY2022 $56,954.48 241
PY2023 $69,801.00 195
PY2024 $84,628.49 271
PY2025 $86,344.38 316

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,711,512.66 170
PY2024 Principal investigator $1,193,584.92 76
PY2023 Recipient $1,231.34 8
PY2023 Principal investigator $1,901,843.40 118
PY2022 Recipient $283.50 1
PY2022 Principal investigator $1,735,645.23 277
PY2021 Recipient $1,747.15 2
PY2021 Principal investigator $1,442,306.37 210
PY2020 Recipient $6,500.60 5
PY2020 Principal investigator $1,189,717.94 200
PY2019 Recipient $692.31 2
PY2019 Principal investigator $1,457,403.01 189

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

170 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $250.92 12/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202533483
Principal investigator 1 ARGENX US, INC. $2,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148552
Principal investigator 1 ARGENX US, INC. $2,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148555
Principal investigator 1 ARGENX US, INC. $447.10 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148559
Principal investigator 1 ARGENX US, INC. $4,560.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148563
Principal investigator 1 ARGENX US, INC. $2,000.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148575
Principal investigator 1 ARGENX US, INC. $2,000.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148577
Principal investigator 1 ARGENX US, INC. $750.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148589
Principal investigator 1 ARGENX US, INC. $1,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148597
Principal investigator 1 ARGENX US, INC. $1,500.00 12/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148601
Principal investigator 1 Janssen Research & Development, LLC $11,325.00 12/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394297
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,399.32 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431094
Principal investigator 1 ABBVIE INC. $2,327.50 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202526532
Principal investigator 1 ABBVIE INC. $1,542.45 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202526534
Principal investigator 1 ABBVIE INC. $6,375.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528640
Principal investigator 1 ABBVIE INC. $842.50 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528642
Principal investigator 1 Janssen Research & Development, LLC $35,250.00 11/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394264
Principal investigator 1 ARGENX US, INC. $1,928.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148545
Principal investigator 1 ARGENX US, INC. $726.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148549
Principal investigator 1 ARGENX US, INC. $5,895.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148571
Principal investigator 1 ARGENX US, INC. $5,835.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148592
Principal investigator 1 ARGENX US, INC. $1,881.00 11/20/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148608
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,424.27 11/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431098
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,995.68 11/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288591
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $87.21 11/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431110
Principal investigator 1 ABBVIE INC. $4,807.50 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520855
Principal investigator 1 ABBVIE INC. $2,462.50 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202520889
Principal investigator 1 ABBVIE INC. $1,542.45 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202520891
Principal investigator 1 Janssen Research & Development, LLC $9,900.00 10/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394291
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,855.98 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLOR
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287011
Principal investigator 1 Janssen Research & Development, LLC $3,775.00 10/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394233
Principal investigator 1 ABBVIE INC. $1,880.45 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202514387
Principal investigator 1 ABBVIE INC. $1,345.00 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202513063
Principal investigator 1 ARGENX US, INC. $108.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148522
Principal investigator 1 ARGENX US, INC. $275.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148525
Principal investigator 1 ARGENX US, INC. $101.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148528
Principal investigator 1 ARGENX US, INC. $3,470.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148531
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148535
Principal investigator 1 ARGENX US, INC. $726.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148538
Principal investigator 1 ARGENX US, INC. $1,881.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148542
Principal investigator 1 ARGENX US, INC. $405.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148567
Principal investigator 1 ARGENX US, INC. $4,560.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148581
Principal investigator 1 ARGENX US, INC. $4,560.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148586
Principal investigator 1 ARGENX US, INC. $371.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148604
Principal investigator 1 ARGENX US, INC. $303.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148611
Principal investigator 1 ARGENX US, INC. $169.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148616
Principal investigator 1 ARGENX US, INC. $81.00 10/02/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148620
Principal investigator 1 Janssen Research & Development, LLC $5,650.00 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394102
Principal investigator 1 Janssen Research & Development, LLC $10,550.00 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394165
Principal investigator 1 Janssen Research & Development, LLC $7,900.00 09/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394191
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $91,632.95 09/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336109
Principal investigator 1 Janssen Research & Development, LLC $12,625.00 08/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394269
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,000.00 08/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431100
Principal investigator 1 ARGENX US, INC. $1,806.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148844
Principal investigator 1 ARGENX US, INC. $1,921.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148848
Principal investigator 1 ARGENX US, INC. $726.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148852
Principal investigator 1 ARGENX US, INC. $4,560.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148855
Principal investigator 1 ARGENX US, INC. $6,402.00 08/13/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148859
Principal investigator 1 Janssen Research & Development, LLC $6,750.00 08/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394222
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $3,000.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243532279
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $10,000.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243532285
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,000.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243532292
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $2,000.00 08/07/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243532297
Principal investigator 1 ABBVIE INC. $6,169.80 08/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202501172
Principal investigator 1 ABBVIE INC. $10,000.00 08/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501174
Principal investigator 1 ABBVIE INC. $4,699.75 08/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501944
Principal investigator 1 ARGENX US, INC. $53.00 08/04/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148874
Principal investigator 1 ARGENX US, INC. $95.50 08/04/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148878
Principal investigator 1 ARGENX US, INC. $1.40 08/04/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148882
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,855.25 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283433
Principal investigator 1 ABBVIE INC. $5,000.00 07/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202500594
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 07/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394120
Principal investigator 1 Amgen Inc. $4,959.85 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC- CLEARWATER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246640333
Principal investigator 1 Janssen Research & Development, LLC $4,350.00 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394257
Principal investigator 1 ARGENX US, INC. $5,895.00 07/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148841
Principal investigator 1 Amgen Inc. $137,827.25 07/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246640343
Principal investigator 1 Janssen Research & Development, LLC $2,750.00 07/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175394279
Principal investigator 1 ABBVIE INC. $7,857.25 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494413
Principal investigator 1 ARGENX US, INC. $37.60 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148862
Principal investigator 1 ARGENX US, INC. $79.50 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148867
Principal investigator 1 ARGENX US, INC. $1.40 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148871
Principal investigator 1 ARGENX US, INC. $191.00 07/01/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 07/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281988
Principal investigator 1 Janssen Research & Development, LLC $3,050.00 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394203
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $76.54 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431108
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,257.90 06/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431096
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,855.25 06/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281864
Principal investigator 1 ARGENX US, INC. $3,296.50 06/23/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148501
Principal investigator 1 ABBVIE INC. $1,680.00 06/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202492555
Principal investigator 1 UCB SA $399.33 06/19/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659643
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148624
Principal investigator 1 ARGENX US, INC. $1.75 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148628
Principal investigator 1 ARGENX US, INC. $6.30 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148632
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148636
Principal investigator 1 ARGENX US, INC. $214.80 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148640
Principal investigator 1 ARGENX US, INC. $573.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148645
Principal investigator 1 ARGENX US, INC. $143.25 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148650
Principal investigator 1 ARGENX US, INC. $668.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148653
Principal investigator 1 ARGENX US, INC. $286.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148657
Principal investigator 1 ARGENX US, INC. $1.05 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148662
Principal investigator 1 ARGENX US, INC. $5.25 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148666
Principal investigator 1 ARGENX US, INC. $3.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148670
Principal investigator 1 ARGENX US, INC. $2.10 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148673
Principal investigator 1 ARGENX US, INC. $77.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148677
Principal investigator 1 ARGENX US, INC. $155.25 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148681
Principal investigator 1 ARGENX US, INC. $21.35 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148686
Principal investigator 1 ARGENX US, INC. $64.05 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148690
Principal investigator 1 ARGENX US, INC. $26.50 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148695
Principal investigator 1 ARGENX US, INC. $382.00 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148699
Principal investigator 1 ARGENX US, INC. $35.80 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148702
Principal investigator 1 ARGENX US, INC. $85.40 06/18/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148706
Principal investigator 1 AstraZeneca UK Limited $8,592.50 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185542928
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,500.00 06/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431106
Principal investigator 1 Janssen Research & Development, LLC $21,100.00 06/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394154
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $23,250.00 06/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225335917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 06/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280688
Principal investigator 1 ABBVIE INC. $2,462.50 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488601
Principal investigator 1 Janssen Research & Development, LLC $250.00 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175394239
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394302
Principal investigator 1 Janssen Research & Development, LLC $800.00 05/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175394178
Principal investigator 1 ARGENX US, INC. $1,824.95 05/19/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148516
Principal investigator 1 Janssen Research & Development, LLC $3,700.00 05/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 05/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279338
Principal investigator 1 ABBVIE INC. $2,500.00 05/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202484331
Principal investigator 1 ABBVIE INC. $3,084.90 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202481445
Principal investigator 1 ABBVIE INC. $4,487.50 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481513
Principal investigator 1 ABBVIE INC. $2,327.50 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481515
Principal investigator 1 ARGENX US, INC. $3,975.60 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148503
Principal investigator 1 ARGENX US, INC. $5,817.60 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148507
Principal investigator 1 ARGENX US, INC. $726.00 04/25/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148510
Principal investigator 1 Janssen Research & Development, LLC $13,550.00 04/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394252
Principal investigator 1 Amgen Inc. $34,527.17 04/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246640337
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,070.00 04/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278096
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $460.00 04/14/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527493
Principal investigator 1 IDORSIA PHARMACEUTICALS US INC $1,345.00 04/14/2025 Non-covered Recipient Entity
Advarra, Inc.
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy No dispute reported 06/30/2026 1243527498
Principal investigator 1 UCB SA $48,510.00 04/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659470
Principal investigator 1 ABBVIE INC. $5,000.00 04/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202475919
Principal investigator 1 Amgen Inc. $85,858.27 04/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246640349
Principal investigator 1 ARGENX US, INC. $1,200.00 04/04/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148513
Principal investigator 1 ABBVIE INC. $10,662.50 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202469588
Principal investigator 1 ABBVIE INC. $2,392.50 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471860
Principal investigator 1 ABBVIE INC. $5,030.80 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202467882
Principal investigator 1 Janssen Research & Development, LLC $14,500.00 03/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175394195
Principal investigator 1 Janssen Research & Development, LLC $1,450.00 03/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175394285
Principal investigator 1 ARGENX US, INC. $2,500.00 03/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148824
Principal investigator 1 ARGENX US, INC. $2,000.00 03/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148828
Principal investigator 1 ARGENX US, INC. $10,000.00 03/24/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148838
Principal investigator 1 Janssen Research & Development, LLC $14,500.00 03/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175394159
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,500.00 03/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431104
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 03/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223276853
Principal investigator 1 Amgen Inc. $3,598.14 03/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639215
Principal investigator 1 Amgen Inc. $17,541.90 03/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH WEST FLORIDA INC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246640363
Principal investigator 1 ABBVIE INC. $6,547.50 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202459381
Principal investigator 1 ABBVIE INC. $5,303.35 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202456571
Principal investigator 1 ABBVIE INC. $100.00 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202458387
Principal investigator 1 Amgen Inc. $45,011.75 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC - CLEARWATER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246640329
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,013.87 03/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431102
Principal investigator 1 Janssen Research & Development, LLC $8,280.00 02/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175394216
Principal investigator 1 ABBVIE INC. $3,171.25 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444533
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,059.00 02/04/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235998010
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $453,013.76 01/30/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235998014
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,173.05 01/27/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235998012
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 01/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA I NC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175394308
Principal investigator 1 Amgen Inc. $28,236.65 01/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INC - CLEARWATER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246640327
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $119,825.00 01/16/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235998020
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $52,904.50 01/13/2025 Non-covered Recipient Entity
Clinical Research Of West Florida
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235998016
Principal investigator 1 ARGENX US, INC. $1,500.00 01/10/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148832
Principal investigator 1 ARGENX US, INC. $1,248.00 01/10/2025 Non-covered Recipient Entity
Clinical Research of West Florida, Inc.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237148835
Principal investigator 1 ABBVIE INC. $4,965.35 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202433477
Principal investigator 1 ABBVIE INC. $2,867.50 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202434193